Title: J&J Boosts Outlook Despite Incoming Tariff Costs
Date: 2025-04-15 15:04
URL: https://finance.yahoo.com/m/7587a6b8-41b1-38a1-b035-d05170727a2f/j%26j-boosts-outlook-despite.html?.tsrc=rss

Oops, something went wrong
Tip: Try a valid symbol or a specific company name for relevant results
Oops, something went wrong
The chipmaker's stock took a hit after it revealed the Trump administration's surprise new controls on exports to China.
Stocks resume slide as Nvidia weighs on tech
Retail sales surged in March at the biggest rate in over two years, in what was the latest sign of the US economy's pre-tariff strength.
Why your water bill is an inflation problem that isn't budging
Stock market today: Dow, S&P 500, Nasdaq futures fall as Nvidia reveals costly limits on China exports
The Treasury secretary told Yahoo Finance that the next 90 days should provide 'substantial clarity' on tariffs
Treasury Secretary Scott Bessent tells Yahoo Finance that the US has a 'big toolkit' to deal with bond market volatility
Stocks drift lower as tariff chaos pauses for a day
The chip giant committed to building AI infrastructure in the US, and Trump says he's going to help make it happen.
The fallout from Trump's tariff whiplash hasn't yet pushed investors to shy away from an old habit
Stocks edge higher after back-to-back rallies with Trump's latest tariff moves in focus
BofA's Moynihan says 'we potentially face a changing economy' after highest-ever equities trading haul
The trade war uncovers new economies of scale
Trump is wrecking his own economic agenda
Higher clothing costs from tariffs are coming soon — but not immediately, experts say
Why Tesla, GM, and Rivian will be hurt most by China's critical minerals export ban
Trump says he's 'looking at something' to help car companies with tariffs
Stocks rally for second straight day, while Apple jumps on tech tariff reprieve
The Nasdaq briefly turned red as stocks' relief rally failed to hold in early afternoon trading
Americans are braced for the biggest unemployment rate jump since the pandemic, a New York Fed survey found
Stocks surge as Apple leads way higher after tech's tariff reprieve
Trump's temporary tech tariff respite adds to a growing sense that he has a willingness to listen and bend
Goldman CEO Solomon warns of 'markedly different operating environment' as dealmaking slows
Corporate earnings take center stage amid tariff turmoil: What to know this week
Trump has tariffs, taxes, and the debt ceiling on a collision course for this summer
Trump denies that there was a tariff “exception” for certain electronics announced Friday. (Bloomberg)
Tax day 2025 is coming up. Here’s what to know to file by the deadline.
Commentary: Put the P/E ratio in timeout for now
Market chaos signals 'sell America' trade as Trump tariff whipsaw threatens to upend the US economy's soft landing
Apple was on brink of crisis before tariff concession from Trump (Bloomberg)
Corporate earnings take center stage amid tariff turmoil: What to know this week
The best (and worst) time of year to buy a house
The Trump family is going all-in on crypto projects, from Bitcoin mining to stablecoins (Bloomberg)
How to invest in gold in 4 steps
Changing jobs can disrupt saving for retirement. Here's how to stay on track.
Trump exempts phones, computers, chips from ‘reciprocal’ tariffs (Bloomberg)
Meet Walmart heir Steuart Walton, the most powerful board member you’ve never heard of
The tariff uncertainty isn't getting any better in markets: Chart of the Week
'T-shirts could be the new eggs': Why Trump's chaotic tariff whipsaw is still a huge threat to inflation
Gold notches best week since 2020 amid 'shaken' investor confidence in US
The bond market just had one of its most volatile and unusual weeks in recent memory
Stocks capped a wild week with a surge higher, as the S&P 500 posted its biggest weekly gain since 2023
Stocks swung into rally mode in afternoon trading, with the major indexes all up over 1%. Bond yields pared bigger gains.
The major indexes whipsawed to end a volatile week. Treasury yields surged in signs of more instability in the bond market.
Consumer sentiment craters further as inflation expectations soar to highest since 1981
Dow, S&P 500, Nasdaq slide as China hits US with tariff hike, bank earnings roll in
JPMorgan's Dimon says economy is facing 'considerable turbulence'
Tariff uncertainty muddies — and refocuses — earnings season
China raises tariffs on US goods to 125% from the 84% planned in response to Trump's latest hike
China already knows Trump's breaking point in their burgeoning trade war, our columnist writes
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
New tariffs, primarily on medical technology products, are projected to add $400 million in costs this year, Chief Financial Officer Joseph Wolk said.
Johnson & Johnson plans to seek a U.S. indication for multiple general surgery procedures, including gastric bypass, which was performed in the clinical trial.
Johnson & Johnson is holding its earnings outlook steady despite President Donald Trump signaling he could put tariffs on the pharmaceutical industry. The administration announced earlier it would conduct an investigation into drug imports. That move is widely seen as a first step toward imposing new levies. Earnings and revenue both beat estimates for the quarter. Johnson & Johnson CFO Joe Wolk joined Bloomberg Open Interest to talk about how tariffs could hit the industry and the drug maker's bottom line.
J&J faces several headwinds at the start of the year, including patent expiry, talc litigation, and, now, tariffs.
J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta from the Intra-Cellular acquisition.
J&J is projecting a $400m hit due to US tariffs in 2025, but reaffirmed its profit outlook while raising its sales forecast.
Pre-markets are down somewhat, following yesterday's +3/4-percent gain on the Dow and the S&P 500, +2/3-percent gain for the Nasdaq.
Per the latest discussion with the FDA, a confirmatory phase III study is required to seek approval for IRWD's apraglutide in short bowel syndrome with intestinal failure.
The average brokerage recommendation (ABR) for Cisco (CSCO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
C's first-quarter 2025 results benefit from a rise in NII and a fall in expenses. Rising loans and deposits balance acts as another positive.
Boeing  stock fell after China ordered its airlines to halt deliveries of the company’s jets as part of an escalating trade war with the U.S., according to a report.  Chinese airlines have been told not to accept any more Boeing deliveries and asked that carriers not buy any further aircraft-related gear from U.S. companies, Bloomberg reported, citing people familiar with the matter.  Boeing didn’t respond to a request for comment.
Tip: Try a valid symbol or a specific company name for relevant results
Sign in to access your portfolio
Try again.